AI주식인사이트AI Stock Insight
B

동구바이오제약

006620KOSDAQ의약품 제조업

63.3 / 100

Reference Date: 2026-06-10

Financial Score25.0 / 40
News Sentiment21.3 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 20.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

DonggubioPharm operates diversified businesses including pharmaceutical manufacturing, new technology investments, marketing services, healthcare services, and pharmaceutical wholesale and consulting. In Q4 2024, its pharmaceutical segment achieved sales of 2,475 billion won, a 15.2% increase compared to the previous year. The company is expanding into new sectors such as biotech investments and medical tourism to enhance growth potential.

Number of Employees

440people

Average Salary

56.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
2.13Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR
0.74Industry Average 0.894.0Point

In line with industry avg

ROE
38.95Industry Average 4.017.0Point

9.7x industry avg (excellent)

Debt Ratio
30.70Industry Average 12.430.0Point

2.5x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼20.1% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 17.3% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,965Won52-week high 6,09052-week low 3,965
1-month return0.0Point

1m -19.98% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-06-05
  • Neutral주식등의대량보유상황보고서(일반)2026-05-26
  • Neutral분기보고서 (2026.03)2026-05-15
  • Neutral주식등의대량보유상황보고서(일반)2026-05-13